AI Hedge Fund Sentient Is Said to Shut After Less Than Two Years

AI Hedge Fund Sentient Is Said to Shut After Less Than Two Years

  • September 9, 2018
Table of Contents

AI Hedge Fund Sentient Is Said to Shut After Less Than Two Years

The fledgling world of AI hedge funds is claiming one of its first casualties. Sentient Investment Management is notifying investors of plans to liquidate the hedge fund it started in late 2016, according to people with knowledge of the situation. The fund managed less than $100 million and hasn’t made money this year after gaining 4 percent in 2017, one of the people said.

Sentient, based in San Francisco, used artificial intelligence techniques, including machine learning and so-called evolutionary algorithms, to trade stocks globally. It followed a market-neutral strategy in which bets on rising prices were matched by wagers on falling ones.

Source: bloomberg.com

Tags :
Share :
comments powered by Disqus

Related Posts

AI chip startup Wave to buy Silicon Valley old-timer MIPS

AI chip startup Wave to buy Silicon Valley old-timer MIPS

Read More
Don’t Learn TensorFlow! Start with Keras or PyTorch Instead

Don’t Learn TensorFlow! Start with Keras or PyTorch Instead

So, you want to learn deep learning? Whether you want to start applying it to your business, base your next side project on it, or simply gain marketable skills – picking the right deep learning framework to learn is the essential first step towards reaching your goal. We strongly recommend that you pick either Keras or PyTorch.

Read More
AI System Approved For Diabetic Retinopathy Diagnosis

AI System Approved For Diabetic Retinopathy Diagnosis

A system designed by a University of Iowa ophthalmologist that uses artificial intelligence (AI) to detect diabetic retinopathy without a person interpreting the results earned Food and Drug Administration (FDA) authorization in April, following a clinical trial in primary care offices. Results of that study were published Aug. 28 online in Nature Digital Medicine, offering the first look at data that led to FDA clearance for IDx-DR, the first medical device that uses AI for the autonomous detection of diabetic retinopathy. The clinical trial, which also was the first study to prospectively assess the safety of an autonomous AI system in patient care, compared the performance of IDx-DR to the gold standard diagnostic for diabetic retinopathy, which is the leading cause of vision loss in adults and one of the most severe complications for the 30.3 million Americans living with diabetes.

Read More